Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions

Melissa D Klein1, Craig R Lee2,3,4, George A Stouffer1,2

  • 1Division of Cardiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Pharmacogenomics
|July 21, 2018
PubMed

Insights

CYP2C19 genotype affects clopidogrel response but not prasugrel or ticagrelor. Genotype-guided antiplatelet therapy shows promise for precision cardiovascular medicine, addressing implementation gaps.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Precision Medicine

Background:

  • CYP2C19 nonfunctional *2 and *3 polymorphisms reduce clopidogrel's effectiveness.
  • This impairment increases cardiovascular event risk after percutaneous coronary intervention.
  • CYP2C19 genotype does not affect prasugrel or ticagrelor response.

Purpose of the Study:

  • To review recent data on CYP2C19 genotype-guided antiplatelet therapy.
  • To provide insight into the clinical utility of this precision medicine approach.
  • To address knowledge gaps impeding widespread implementation.

Main Methods:

  • Critical evaluation of recent studies.
  • Analysis of clinical outcomes data.
  • Review of current clinical practice guidelines.

Main Results:

  • Recent studies are evaluating the impact of CYP2C19 genotype-guided antiplatelet selection on clinical outcomes.
  • Data is beginning to clarify the clinical utility of this approach.
  • Uncertainty regarding implementation is decreasing.

Conclusions:

  • CYP2C19 genotype is a critical factor for clopidogrel efficacy.
  • Prasugrel and ticagrelor offer alternative antiplatelet options independent of CYP2C19 genotype.
  • Genotype-guided antiplatelet therapy represents a significant advancement in precision cardiovascular medicine.

Related Concept Videos

The Evidence for Evolution02:55

The Evidence for Evolution

Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
48.3K
Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.9K
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
107.3K
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
4.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K